{
    "title": "To provide for the establishment of certain restrictions with respect to drugs containing isotretinoin (including the drug marketed as Accutane).",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Accutane Safety and Risk Management \nAct''.\n\nSEC. 2. FEDERAL FOOD, DRUG, AND COSMETIC ACT; RESTRICTIONS REGARDING \n              DRUG ISOTRETINOIN.\n\n    (a) In General.--Not later than the expiration of the 30-day period \nbeginning on the date of the enactment of this Act, the Secretary of \nHealth and Human Services (referred to in this Act as the \n``Secretary''), acting through the Commissioner of Food and Drugs, \nshall withdraw the approval under section 505 of the Federal Food, \nDrug, and Cosmetic Act of each application for a drug that contains \nisotretinoin as an active ingredient (including the drug marketed as \nAccutane). During or after such period, any holder of an application \nthat is subject to the preceding sentence may file with the Secretary a \nsupplemental application for such drug, and the Secretary may approve \nthe supplemental application in accordance with subsection (b).\n    (b) Restrictions.--Any approval by the Secretary of a supplemental \napplication for a drug containing isotretinoin pursuant to subsection \n(a) shall provide that such drug is being approved as a drug subject to \nsubpart H of part 314 of title 21, Code of Federal Regulations. The \nSecretary shall under such subpart H establish restrictions on the \ndistribution of the drug. Such restrictions shall require that \ndistribution of the drug under all the approved supplemental \napplications be exclusively through a single program, approved by the \nSecretary, that provides for the distribution of the drug in accordance \nwith the following conditions:\n            (1) Distribution of the drug by manufacturers is directly \n        to pharmacists (without the involvement of entities engaged in \n        the wholesale distribution of drugs), and each pharmacist \n        receiving the drug is in compliance with the following:\n                    (A) The pharmacist has registered with the program.\n                    (B) The pharmacist has received education on \n                potential side effects of the drug relating to birth \n                defects and mental health or behavioral issues that, as \n                of the day before the date of the enactment of this \n                Act, were described on the approved labeling for the \n                drug (including depression, suicidal ideation, suicide \n                attempts, suicide, and aggressive or violent behavior).\n                    (C) The pharmacist agrees that the drug will be \n                dispensed only pursuant to prescriptions issued by \n                practitioners at treatment centers certified under \n                paragraph (2).\n                    (D) The pharmacist has signed and filed with the \n                program a statement that the pharmacist understands the \n                conditions for participation in the program as a \n                pharmacist, and will maintain compliance with the \n                agreement described in subparagraph (C) and otherwise \n                comply with applicable conditions.\n            (2) The program certifies clinics and medical offices as \n        treatment centers regarding the drug, makes the certifications \n        in accordance with the conditions described in subsection (c), \n        provides that the certifications are effective for one year, \n        and maintains a registry of treatment centers for which \n        certifications are in effect.\n            (3) The program develops and makes available to \n        practitioners materials for educating patients on the drug, \n        including managing the risks associated with the drug, and such \n        materials include a questionnaire, to be completed monthly by \n        patients, that warns patients of the adverse side effects \n        described in paragraph (1)(B) and monitors for the development \n        of any such effects in patients.\n            (4) The drug is prescribed for a patient by a practitioner \n        only in accordance with the following:\n                    (A) The drug is prescribed for severe, recalcitrant \n                nodular acne that is unresponsive to conventional \n                therapy, including antibiotics.\n                    (B) The patient is registered with the program.\n                    (C) Using the materials referred to in paragraph \n                (3), the practitioner educates the patient on the drug, \n                including providing one-on-one, in-person counseling.\n                    (D) The practitioner provides to the patient the \n                questionnaire referred to in paragraph (3), and the \n                patient completes the questionnaire.\n                    (E) The patient signs a statement providing the \n                informed consent of the patient to undergo treatment \n                with the drug (or a parent or guardian of the patient \n                signs the statement, in the case of a patient who is a \n                minor or otherwise lacks legal capacity).\n                    (F) The patient undergoes the appropriate blood \n                tests.\n                    (G) In the case of a female patient--\n                            (i) the education under subparagraph (C) \n                        includes education on the need to avoid \n                        becoming pregnant while being treated with the \n                        drug; and\n                            (ii) the practitioner determines that the \n                        patient is not pregnant, as indicated by an \n                        electronic verification, provided to the \n                        practitioner by an accredited laboratory, that \n                        the patient has undergone a pregnancy test and \n                        received a negative result.\n                    (H) In the case of a male patient, the education \n                under subparagraph (C) includes education on the need \n                to avoid impregnating women while being treated with \n                the drug.\n                    (I) The prescription is issued only after \n                compliance with subparagraphs (B) through (H).\n                    (J) The prescription is for a 30-day supply of the \n                drug, with no refills.\n                    (K) Each further prescription for the drug is \n                issued by the practitioner to the patient only pursuant \n                to another in-person consultation with the \n                practitioner, and prior to issuing the prescription, \n                compliance with subparagraphs (C) through (I) is \n                repeated.\n                    (L) The patient undergoes the appropriate blood \n                tests 30 days after the conclusion of treatment with \n                the drug.\n            (5) Such additional conditions as the Secretary may by \n        regulation determine to be necessary to protect the public \n        health with respect to the drug.\n    (c) Certification of Treatment Centers.--For purposes of subsection \n(b)(2), the conditions for the program to certify a clinic or medical \noffice as a treatment center regarding a drug containing isotretinoin \nare as follows:\n            (1) The program determines that each of the practitioners \n        at the clinic or office who will prescribe the drug is in \n        compliance with the following:\n                    (A) The practitioner is authorized under the law of \n                the State involved to administer prescription drugs.\n                    (B) The practitioner has registered with the \n                program and received education on the potential side \n                effects referred to in subsection (b)(1)(B).\n                    (C) The practitioner agrees as follows:\n                            (i) The practitioner will prescribe the \n                        drug for a patient in accordance with \n                        subsection (b)(4).\n                            (ii) If a female patient being treated with \n                        the drug becomes pregnant, the practitioner \n                        will immediately report the pregnancy to the \n                        program and provide follow-up in accordance \n                        with the program.\n                            (iii) The practitioner will not issue \n                        prescriptions for the drug by telephone or \n                        facsimile transmission, or through the \n                        Internet.\n                            (iv) The practitioner will--\n                                    (I) report to the Secretary any \n                                information received by the \n                                practitioner on adverse events that are \n                                associated with the use of the drug by \n                                patients of the practitioner; and\n                                    (II) submit such reports quarterly, \n                                except in the case of a patient death \n                                associated with the drug, in which case \n                                the report will be submitted \n                                immediately, but in no case later than \n                                15 days after the date on which the \n                                practitioner learns of the death.\n                    (D) The practitioner has signed and filed with the \n                program a statement that the practitioner understands \n                the conditions for participation in the program as a \n                practitioner, and will maintain compliance with the \n                agreements described in subparagraph (C) and otherwise \n                comply with applicable conditions.\n            (2) After the initial certification of the clinic or \n        office, the program renews a certification for additional one-\n        year periods only if the program has conducted an evaluation to \n        determine whether, during the preceding one-year period, each \n        practitioner at the center who prescribes the drug has \n        maintained substantial compliance with applicable conditions of \n        the program.\n            (3) Such additional conditions as the Secretary may by \n        regulation determine to be necessary to protect the public \n        health with respect to the drug.\n    (d) Monitoring by Secretary.--The Secretary shall monitor the \ndistribution of drugs containing isotretinoin under supplemental \napplications approved under subsection (b), including the prescribing \nand dispensing of the drug, to determine whether the drug is being \ndistributed in accordance with the program approved by the Secretary \nunder such subsection.\n    (e) Additional Approved Uses.--\n            (1) In general.--With respect to a drug that contains \n        isotretinoin as an active ingredient, this section may not be \n        construed as prohibiting the Secretary from approving an \n        application under section 505 of the Federal Food, Drug, and \n        Cosmetic Act for such a drug for a use different than the use \n        described in subsection (b)(4)(A) (which different use is \n        referred to in this subsection as a ``new use'').\n            (2) Conditions.--For purposes of paragraph (1):\n                    (A) An approval by the Secretary of a new use is \n                subject to the same conditions as apply under \n                subsection (b) with respect to the use described in \n                paragraph (4)(A) of such subsection.\n                    (B) In applying such conditions to the new use, the \n                Secretary may authorize the program under subsection \n                (b) to be expanded to include the new use, or the \n                Secretary may require the establishment of a separate \n                program for the new use.\n                    (C) The requirement of monitoring under subsection \n                (d) applies with respect to the new use to the same \n                extent and in the same manner as the requirement \n                applies with respect to the use described in subsection \n                (b)(4)(A).\n                    (D) Section 3 applies with respect to the new use.\n\nSEC. 3. REPORTING OF ADVERSE EVENTS BY MANUFACTURERS AND DISTRIBUTORS.\n\n    (a) In General.--Each person who is a manufacturer or distributor \nof a drug containing isotretinoin shall report to the Secretary any \ninformation received by such person on adverse events that are \nassociated with such drug. In any case in which an individual reports \nan adverse event to such person and states that the individual believes \nthe drug is a factor in the event, the person shall consider the event \nto be associated with the drug for purposes of the preceding sentence.\n    (b) Timeframe for Reporting.--A person described in subsection (a) \nshall submit reports under such subsection to the Secretary on a \nquarterly basis, except that in the case of a death associated with \nisotretinoin, the report shall be submitted immediately, but in no case \nlater than 15 days after the date on which the person learns of the \ndeath.\n\nSEC. 4. FURTHER STUDIES.\n\n    (a) In General.--The Secretary, in consultation with the Director \nof the Centers for Disease Control and Prevention, the Director of the \nNational Institutes of Health, and the Director of the National \nInstitute of Mental Health, shall continue to conduct and support \nappropriate studies to explore, in adolescents and adults--\n            (1) the effects of isotretinoin and retinoid acid on the \n        central nervous system, including the brain; and\n            (2) the behavioral effects of isotretinoin, including \n        depression, suicidal ideation, suicide attempts, suicide, and \n        aggressive or violent behavior.\n    (b) Authorization of Appropriations.--For the purpose of studies \nunder subsection (a), there are authorized to be appropriated such sums \nas may be necessary for fiscal year 2006 and each subsequent fiscal \nyear, in addition to any other authorizations of appropriations that \nare available for such purpose."
}